Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Cell Reprogramming in Hematopoiesis and Immunity

PEREIRA group

Our research

The focus of our laboratory is to understand the molecular determinants underlying cell reprogramming and hematopoietic specification. In humans, the multiple differentiated cell states are normally stable and inherited through cell division. Under certain conditions, cell fate can, however, be modified or reversed. Cell reprogramming can be achieved experimentally in different ways, including nuclear transfer, cell fusion or expression of transcription factors. The emergent ability to directly reprogram somatic cells into desired hematopoietic cell-types is opening avenues to the discovery of new therapies for immune and blood diseases. Our approach focuses on Hematopoietic Stem Cells (HSCs) for their remarkable regenerative potential and Dendritic Cells (DCs) as key orchestrators of immunity.

Aims

  • To understand at the molecular level how hematopoietic cellular identities are specified during development employing cellular reprogramming.
  • To use this knowledge to design new strategies for regenerative medicine and cancer immunotherapy.

Impact

Our research will increase the understanding of the intrinsic determinants underlying hematopoietic progenitor and effector cell identities. This knowledge may allow the re-creation of these unique cell fates from any human cell in the dish or inside the organism. Ultimately, we believe that our research will contribute to improved blood stem cell transplantation and hematopoietic regeneration. In addition, DC reprogramming is allowing us to develop new ways to modulate the immune response. This represents a unique opportunity to merge the fields of cell reprogramming and cancer immunotherapy, leading to the development of a powerful new class of cancer therapeutics.

List of Team Pereira's publications


Team

(name linked to profile in Lund University research portal)

Filipe Pereira  

Principal Investigator, Filipe [dot] Pereira [at] med [dot] lu [dot] se 

Hreinn Benonisson

Postdoc, Hreinn [dot] Benonisson [at] med [dot] lu [dot] se

Ilia Kurochkin

Postdoc, Ilia [dot] Kurochkin [at] med [dot] lu [dot] se

Cristiana Pires 

Postdoc, Cristiana [dot] Pires [at] med [dot] lu [dot] se 

Olga Zimmermannova 

Postdoc, Olga [dot] Zimmermannova [at] med [dot] lu [dot] se

Rita Alves 

PhD student, Rita [dot] Alves [at] med [dot] lu [dot] se 

Inês Caiado

PhD student, Ines [dot] Caiado [at] med [dot] lu [dot] se

Alexandra Ferreira 

PhD student, Alexandra_Gabriela [dot] Ferreira [at] med [dot] lu [dot] se 

Fabio Rosa 

PhD student, Fabio_Alexandre [dot] Fiuza_Rosa [at] med [dot] lu [dot] se 

Abigail Altman

Master student, Abigail [dot] Altman [at] med [dot] lu [dot] se

Nejc Arh

Master student, ne1856ar-s [at] student [dot] lu [dot] se

Ervin Ascic

Master student, Ervin [dot] Ascic [at] med [dot] lu [dot] se

Diego Soto Cabrera

Master student, diego [dot] soto_cabrera [at] med [dot] lu [dot] se

 

Pereira banner

FILIPE PEREIRA

 

Filip Pereira

Principal Investigator
PhD, Associate Professor
WCMM
Division of Molecular Medicine & Gene Therapy
Department of Laboratory Medicine
Lund Stem Cell Center
BMC A12, Lund University
221 84 Lund, Sweden

Phone: +46 46 222 49 19 
Email:  Filipe [dot] Pereira [at] med [dot] lu [dot] se 
Webpage:  https://pereiralab.com/

Profile in Lund University research portal